TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03180827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian tissue biopsy
Description: ovarian tissue biopsy during general anesthesia
Study: NCT00328965

Intervention type: DRUG
Group type: OTHER
Intervention: Lacidipine
Description: Lacidipine 2, 4, 6mg
Study: NCT01522625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate 300mg per day
Description: tenofovir disoproxil fumarate 300mg per day for 3 years
Study: NCT04422431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bis-Choline Tetrathiomolybdate
Description: Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
Study: NCT02568553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study: NCT01533077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg of BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg of BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25 mg
Description: immediate-release levodopa/carbidopa 100/25 (single-dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25 mg
Description: immediate-release levodopa/carbidopa 100/25 (single-dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25 mg
Description: immediate-release levodopa/carbidopa 100/25 (single-dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25 mg
Description: immediate-release levodopa/carbidopa 100/25 (single-dose).
Study: NCT00781274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: 750 mg every 8 hours for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 24 weeks
Study: NCT01218243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle
Description: For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: needle
Description: For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
Study: NCT00807170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib)
Description: 100 mg as a once daily oral dose, 21 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiotherapy (WBRT)
Study: NCT01717820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried whole-grape powder
Description: Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
Study: NCT01346982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silimarine
Description: darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
Study: NCT01522625

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, identical to TDF in appearance, once daily for 3years
Study: NCT00567541

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Battery Powered Microneuromodulator (BBPM)
Description: The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
Study: NCT02779998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non invasive ventilation
Description: non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy with facial mask
Study: NCT04421261

Intervention type: DEVICE
Intervention: Air-Q Self Pressurized Airway Device with Blocker
Description: used in low risk adult females undergoing elective surgeries

Intervention type: DEVICE
Intervention: Proseal Laryngeal Mask Airway
Description: used in low risk adult female patients undergoing elective surgeries
Study: NCT02178423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound for diagnosis of CVC position in children
Description: Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
Study: NCT00807170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: 200 mg as a once daily oral dose, 21 days
Study: NCT05372146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GSV radiofrequency ablation with concomitant phlebectomy
Description: Radiofrequency ablation with concomitant phlebectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GSV radiofrequency ablation with concomitant phlebectomy
Description: Radiofrequency ablation with concomitant phlebectomy
Study: NCT00214331

Intervention type: DRUG
Intervention: ciprofloxacin
Description: ciprofloxacin 500 mg twice a day for five doses.

Intervention type: DRUG
Intervention: azithromycin
Description: azithromycin 500 mg on day 1 followed by 250 mg on days 2-5

Intervention type: DRUG
Intervention: gentamicin
Description: a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
Study: NCT04594174

Intervention type: PROCEDURE
Intervention: Fluid administration
Description: Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP \<65 mm Hg or a Systolic Blood Pressure \<90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase.

Intervention type: PROCEDURE
Intervention: Fluid administration
Description: Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP \<65 mm Hg or a Systolic Blood Pressure \<90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase.
Study: NCT00468078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: 10min acquisition, 90min after injection of F-18 FPCIT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT
Description: 10min acquisition, 90min after injection of F-18 FPCIT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FPCIT
Description: 5mCi, intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18 FPCIT
Description: 5mCi, intravenous injection
Study: NCT04626752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T
Description: Volunteers will be treated with BCMA CAR-T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/㎡ for D-4、D-3 and D-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/㎡ for D-3 and D-2
Study: NCT01362465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy
Description: Implanting device to measure delays between paced chambers in heart failure patients.
Study: NCT04439773

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group will be given the same volume of saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
Study: NCT04289506

Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA expression
Description: The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).

Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA expression
Description: The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).

Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA expression
Description: The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).

Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA expression
Description: The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).

Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA expression
Description: The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
Study: NCT04284514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778 Ophthalmic Solution
Description: AKB-9778 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Matched vehicle-control
Study: NCT03130114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
Study: NCT00781521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofloxacin otic solution 0.3%
Description: ofloxacin otic solution 0.3% instilled twice a day for seven days
Study: NCT04076670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention for family caregivers of patients at the end of life
Description: The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
Study: NCT02939014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin IV infusion
Study: NCT01252875

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Target : 100 mg/dL (+/-10 mg/dL)
Description: Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 70 mg/dL
Description: Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
Study: NCT00876018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Description: Fortified nutritional powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Un-fortified nutritional powder
Study: NCT02568553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT02480218

Intervention type: OTHER
Intervention: Neuropsychological test battery
Description: Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.

Intervention type: OTHER
Intervention: Neuropsychological test battery
Description: Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
Study: NCT01302236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
Study: NCT00521755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seraffix LTB
Description: laser soldering for soft tissue wounds
Study: NCT03113266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody toripalimab
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study: NCT02545855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy
Description: All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy
Description: All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy (HOT)
Description: All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy (HOT)
Description: All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
Study: NCT02422914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation program TFC and activity tracker
Description: Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking cessation program TFC-free and activity tracker
Description: Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.~The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation program and activity tracker
Description: Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
Study: NCT02106650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn and Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
Study: NCT04288089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib (75, 100, 125 milligram [mg])
Description: Palbociclib orally, once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6545 (150, 300, 450 mg)
Description: H3B-6545 orally, QD.
Study: NCT00567541

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Battery Powered Microneuromodulator (BBPM)
Description: The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
Study: NCT03314558

Intervention type: OTHER
Intervention: pulmonary rehabilitation
Description: a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
Study: NCT03785795

Intervention type: DEVICE
Intervention: Uncertain diagnosis of true labor
Description: Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
Study: NCT01404442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo(distilled water
Description: The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
Study: NCT02217228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sebacia microparticles and laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vehicle suspension and laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sebacia microparticles without laser
Study: NCT01583452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: The use of chewing gum as a preventive measure for post-operative ileus